Table 3.

Associations of mineral metabolite (FGF23, 1,25[OH]2D, and 25[OH]D) and genotype interactions with annualized change in eGFR in HALT-PKD study A and B

Associationβ-Estimate (95% CI)
FGF23 × Genotype1,25(OH)2D × Genotype25(OH)D × Genotype
UnadjustedAdjustedUnadjustedAdjustedUnadjustedAdjusted
PKD1 truncating × mineral metaboliteReferenceReferenceReferenceReferenceReferenceReference
PKD1 nontruncating × mineral metabolite−0.47 (−1.63 to 0.69)−0.51 (−1.66 to 0.63)0.05 (0.00 to 0.10)0.05 (−0.00 to 0.09)−0.01 (−0.05 to 0.04)−0.00 (−0.05 to 0.04)
PKD2 × mineral metabolite0.85 (−0.57 to 2.26)0.65 (−0.75 to 2.05)0.01 (−0.05 to 0.07)0.01 (−0.05 to 0.06)−0.02 (−0.09 to 0.05)−0.01 (−0.08 to 0.05)
NMD × mineral metabolite−0.38 (−2.37 to 1.61)−0.49 (−2.46 to 1.49)0.04 (−0.03 to 0.11)0.04 (−0.03 to 0.11)0.00 (−0.11 to 0.11)0.02 (−0.09 to 0.12)
  • Adjusted model is adjusted for age, sex, body mass index, systolic BP, randomization group, calcium, phosphorus, baseline eGFR, baseline height-adjusted total kidney volume, and urinary albumin excretion. FGF23, fibroblast growth factor 23; 1,25(OH)2D, 1,25-dihydroxyvitamin D; 25(OH)D, 25-hydroxyvitamin D; HALT-PKD, Halt Progression of Polycystic Kidney Disease; NMD, no mutation detected.